verapamil has been researched along with Atherosclerotic Parkinsonism in 3 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 7.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
| "Based on the hypothesis that low-threshold calcium conductance in the thalamus might be involved in the pathophysiology of parkinsonian tremor, ethosuximide was given chronically to a monkey previously treated with MPTP and displaying exceptionally a typical rest tremor." | 3.68 | Effect of ethosuximide on rest tremor in the MPTP monkey model. ( Bédard, PJ; Boucher, R; Gomez-Mancilla, B; Latulippe, JF, 1992) |
| " This seems to be a rare side effect as there have only been three other reported cases of secondary extrapyramidal syndromes in the literature." | 2.38 | [Parkinson syndrome, a possible adverse effect of calcium inhibitors]. ( Lauribe, P; Lévy, S; Malaterre, HR; Paganelli, F; Ramond, B, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Padrell, MD | 1 |
| Navarro, M | 1 |
| Faura, CC | 1 |
| Horga, JF | 1 |
| Malaterre, HR | 1 |
| Lauribe, P | 1 |
| Paganelli, F | 1 |
| Ramond, B | 1 |
| Lévy, S | 1 |
| Gomez-Mancilla, B | 1 |
| Latulippe, JF | 1 |
| Boucher, R | 1 |
| Bédard, PJ | 1 |
1 review available for verapamil and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
[Parkinson syndrome, a possible adverse effect of calcium inhibitors].
Topics: Aged; Calcium Channel Blockers; Diltiazem; Female; Humans; Male; Parkinson Disease, Secondary; Verap | 1992 |
2 other studies available for verapamil and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Verapamil-induced parkinsonism.
Topics: Aged; Female; Humans; Hypertension; Parkinson Disease, Secondary; Vasodilator Agents; Verapamil | 1995 |
Effect of ethosuximide on rest tremor in the MPTP monkey model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Diltiazem; Dopamine Agents; Dose-Response Rel | 1992 |